Table 2 The treatment planning dose-volume constraints for the SPARK protocol
Constraint | Per-Protocol | Minor Variation | Major Variation |
|---|---|---|---|
PTV D95% | 36.0–36.5Gy (100%) | <36.0Gy or >36.5 Gy | |
PTV D98% | ≥34.44 Gy (95%) | 32.72– <34.44 Gy | <32.72 Gy |
PTV D2% | ≤38.06 Gy (105%) | >38.06–39.96 Gy | >39.96 Gy |
PTV Dmax to 0.1 cc | ≤38.78 Gy (107%) | >38.78–40.72 Gy | >40.72 Gy |
PTV Dmax | Not within a critical structure | N/A | Within a critical structure |
Rectum Dmax to 0.1 cc | ≤38.06 Gy (105%) | >38.06–39.96 Gy | >39.96 Gy |
Rectum V34.4 Gy | ≤3 cc | >3–4 cc | >4 cc |
Rectum V18.13 Gy | ≤50% | >50–60% | >60% |
Rectum V29 Gy | ≤20% | >20–25% | >25% |
Rectum V32.63 Gy | ≤5% | >5–10% | >10% |
Bladder Dmax to 0.1 cc | ≤38.06 Gy (105%) | >38.06 or 39.96 Gy | >39.96 Gy |
Bladder V34.4 Gy | ≤10 cc | >10–12 cc | >12 cc |
Bladder V18.13 Gy | ≤50% | >50–60% | >60% |
Bladder V32.63 Gy | ≤10% | >10–15% | >15% |
Urethra_PRV Dmax 0.1 cc | ≤38.78 Gy (107%) | >38.78–40.72 Gy | >40.72 Gy |
Urethra_PRV V38.0 Gy | ≤5% | >5–7% | >7% |
FemHead_R, FemHead_L V20 Gy | ≤10 cc | >10–14 cc | >14 cc |
FemHead_R, FemHead_L Dmax to 0.1 cc | ≤30 Gy | >30–32 Gy | >32 Gy |
PenileBulb Dmax 0.1 cc | ≤36.25 Gy | n/a | n/a |
PenileBulb V20 Gy | ≤ 1 cc | n/a | n/a |
Intermediate dose spillage: ratio of volumes receiving 50% TD to 100% TD | ≤4 | >4–5 | >5 |
Conformity Index (volume receiving 36.25 Gy/volume of PTV): | ≤1.1 | >1.1–1.2 | >1.2 |
RVR V36.25 Gy | ≤5 cc | >5–7 cc | >7 cc |